Immatics N.V. logo

Immatics N.V.

NASDAQ:IMTX

Overview | Financials
Company Name Immatics N.V.
Symbol IMTX
Currency USD
Price 5.09
Market Cap 618,689,500
Dividend Yield 0%
52-week-range 3.3 - 13.09
Industry Biotechnology
Sector Healthcare
CEO Dr. Harpreet Singh Ph.D.
Website https://www.immatics.com

An error occurred while fetching data.

About Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell

Related Stocks

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

12.05 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

7.11 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

0.68 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

5 USD

Immunovant, Inc. logo

Immunovant, Inc.

IMVT

14.69 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

17.01 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

5.32 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

9.34 USD

908 Devices Inc. logo

908 Devices Inc.

MASS

6.25 USD

Financials

Numbers are in millions USD

Numbers are in millions USD